FENNEC PHARMACEUTICALS INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that FENNEC PHARMACEUTICALS INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.64M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $47.54M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $21.25M | Mar 26, 2025 |
| FY2023 | Sep 30, 2023 | $6.30M | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | $1.54M | Mar 29, 2024 |
| FY2021 | Dec 31, 2020 | $170.0K | Feb 28, 2022 |
| FY2019 | Dec 31, 2019 | $0 | Feb 14, 2020 |
| FY2019 | Dec 31, 2018 | $0 | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Mar 28, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $19.99M | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | $1.45M | Mar 29, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.74M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($436.0K) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($16.05M) | Mar 26, 2025 |
| FY2023 | Sep 30, 2023 | $917.0K | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | ($23.71M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($17.35M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($18.11M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($12.78M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($9.89M) | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | ($7.05M) | Mar 15, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.28M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $2.57M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($12.77M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($22.59M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($17.22M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($17.89M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($13.01M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($10.41M) | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | ($6.95M) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | ($2.87M) | Mar 28, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $250.0K | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $307.0K | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $56.0K | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $3.53M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $4.98M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $5.11M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $5.61M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $5.01M | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $1.94M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $472.0K | Mar 28, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.47M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $26.98M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($17.14M) | Mar 26, 2025 |
| FY2023 | Sep 30, 2023 | ($12.28M) | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | ($18.06M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($14.22M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($15.60M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($9.06M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($7.83M) | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | ($3.64M) | Mar 15, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $0 | Mar 31, 2014 |
| FY2013 | Dec 31, 2012 | $0 | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $0 | Apr 1, 2013 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $70.55M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $44.95M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $26.86M | Mar 26, 2025 |
| FY2023 | Sep 30, 2023 | $19.98M | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | $26.94M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $22.41M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $31.42M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $14.15M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $22.95M | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $28.40M | Mar 15, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.08M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $50.82M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $38.49M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $29.51M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $6.64M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $2.35M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $2.27M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $1.64M | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $1.64M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $402.0K | Mar 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.47M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($5.87M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2023 | ($11.62M) | Mar 27, 2026 |
| FY2023 | Sep 30, 2023 | $9.58M | Mar 29, 2024 |
| FY2024 | Dec 31, 2022 | ($2.57M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | $15.77M | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | $29.07M | Mar 29, 2023 |
| FY2021 | Dec 31, 2019 | $11.88M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $21.31M | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | $26.76M | Feb 14, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($229.42M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($219.68M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($219.25M) | Mar 26, 2025 |
| FY2023 | Sep 30, 2023 | $215.61M | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | ($203.20M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($179.49M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($162.14M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($144.03M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($131.26M) | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | ($121.37M) | Mar 15, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.79M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $26.63M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $13.27M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $23.77M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $21.10M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $30.34M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $13.65M | Mar 30, 2021 |
| FY2020 | Dec 31, 2018 | $22.78M | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | $28.26M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $3.93M | Mar 15, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $19.34M | Mar 26, 2025 |
| FY2023 | Dec 31, 2023 | $30.93M | Mar 29, 2024 |
| FY2022 | Dec 31, 2022 | $24.90M | Mar 29, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 26, 2025 |
| FY2023 | Sep 30, 2023 | 0 | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Feb 28, 2022 |
| FY2015 | Dec 31, 2015 | 0 | Mar 28, 2016 |
| FY2015 | Dec 31, 2014 | 0 | Mar 28, 2016 |
| FY2014 | Dec 31, 2013 | 0 | Mar 31, 2015 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 26, 2025 |
| FY2023 | Sep 30, 2023 | 0 | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Feb 28, 2022 |
| FY2015 | Dec 31, 2015 | 0 | Mar 28, 2016 |
| FY2015 | Dec 31, 2014 | 0 | Mar 28, 2016 |
| FY2014 | Dec 31, 2013 | 0 | Mar 31, 2015 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 34.16M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 27.53M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 27.03M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | 26.36M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 26.01M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | 26.00M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 19.90M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 19.90M | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | 18.41M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | 13.64M | Mar 28, 2018 |